The US FDA conducted a Good Manufacturing Practices (GMP) inspection of Sun Pharmaceutical Industries Ltd.'s Halol facility (Gujarat, India) from February 12-23, 2018. At the conclusion of the inspection, the agency issued a Form 483, with three observations. The company is preparing the response to the observations, which will be submitted to the US FDA within 15 business days. The company is committed to addressing these observations promptly.
The company remains committed to working closely with the US FDA and continues to enhance its GMP compliance on an ongoing basis.
Shares of SUN PHARMACEUTICAL INDUSTRIES LTD. was last trading in BSE at Rs.570.2 as compared to the previous close of Rs. 542.15. The total number of shares traded during the day was 2910655 in over 29716 trades.
The stock hit an intraday high of Rs. 575 and intraday low of 546.2. The net turnover during the day was Rs. 1634768625.